BioCentury on BioBusiness,
CRADA pricing challenged
Monday, July 25, 1994
By Steve Usdin
WASHINGTON - Members of an NIH advisory panel on Friday excoriated the reasonable pricing clause in the NIH model Cooperative Research and Development Agreement after hearing representatives of industry, academia and NIH describe the negative impact it has had on government-industry cooperation.
The panel members are consultants to the Advisory Committee to the NIH Director (ACD). The ACD meets twice annually and will consider the results of the deliberations when it meets again in September. A report based on the panel's discussions will be forwarded to NIH Director Harold Varmus.
Varmus started the day's deliberations by telling the committee that another NIH panel concluded in December that sponsored research agreements work well and were in compliance with the Bayh-Dole technology transfer act.
However, he said, there is anxiety at NIH regarding "the cumbersome nature of the process by which CRADAs are worked out, the fact that the number of CRADAs has not increased relative to research agreements at
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]